Armistice Capital LLC recently announced the acquisition of new stake in Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH). The institutional investor has increased its shareholding in the Healthcare company by 590.61% to 5.0 million shares with purchase of 4.28 million shares. This fresh investment now brings its stake to 3.51% valued currently at $56.25 million. In addition, Citadel Advisors LLC raised its holdings by 0.91 million to 3.36 million shares. And SSgA Funds Management, Inc. has lifted its position by 0.33% or 8113.0 shares – to 2.45 million shares.
With over 1.62 million Aurinia Pharmaceuticals Inc. (AUPH) shares trading Friday and a closing price of $10.64 on the day, the dollar volume was approximately $17.26 million. The shares have shown a positive half year performance of 115.38% and its price on 05/19/23 lost nearly -0.93%. Currently, there are 142.64M common shares owned by the public and among those 132.88M shares have been available to trade.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
Sponsored
An analysis of what Wall Street brokers have to say about the expected price targets for this stock gives us this picture: 8 analysts who have offered their price forecasts for AUPH have a consensus price objective of $13.71. The analysts have set the share’s price value over the next 12 months at a high of $15.00 and a low of $12.00. The average price target is 33.5% above its recent price level and an upside to the estimated low will see the stock gain 11.33% over that period. But an upside of 29.07% will see the stock hit the forecast high price target while median target price for the stock is $14.00.
The top 3 mutual fund holders in Aurinia Pharmaceuticals Inc. are iShares Russell 2000 ETF, Fidelity Small Cap Index Fund, and CREF Stock Account. iShares Russell 2000 ETF owns 2.85 million shares of the company’s stock, all valued at over $32.04 million. The company sold 41680.0 shares recently to bring their total holdings to about 2.00% of the shares outstanding. Fidelity Small Cap Index Fund bought 20675.0 shares to see its total holdings expand to 1.13 million shares valued at over $12.67 million and representing 0.79% of the shares outstanding. CREF Stock Account bought 8780.0 shares to bring its total holdings to over 1.11 million shares at a value of $12.45 million. CREF Stock Account now owns shares totaling to 0.78% of the shares outstanding.
Shares of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) opened at $10.87, up $0.13 from a prior closing price of $10.74. However, the script later moved the day high at 10.94, down -0.93%. The company’s stock has a 5-day price change of -0.93% and 29.91% over the past three months. AUPH shares are trading 146.30% year to date (YTD), with the 12-month market performance down to -5.08% lower. It has a 12-month low price of $4.07 and touched a high of $13.41 over the same period. AUPH has an average intraday trading volume of 3.10 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by -3.85%, 1.07%, and 33.42% respectively.
Institutional ownership of Aurinia Pharmaceuticals Inc. (NASDAQ: AUPH) shares accounts for 40.50% of the company’s 142.64M shares outstanding. Mutual fund holders own 10.43%, while other institutional holders and individual stakeholders account for 25.81% and 0.40% respectively.
It has a market capitalization of $1.54B and a beta (3y monthly) value of 1.18. The earnings-per-share (ttm) stands at -$0.68. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.03% over the week and 5.45% over the month.
Analysts forecast that Aurinia Pharmaceuticals Inc. (AUPH) will achieve an EPS of -$0.18 for the current quarter, -$0.17 for the next quarter and -$0.42 for 2024. The lowest estimate earnings-per-share for the quarter is -$0.22 while analysts give the company a high EPS estimate of -$0.16. Comparatively, EPS for the current quarter was -$0.25 a year ago. Earnings per share for the fiscal year are expected to increase by 45.50%, and 38.20% over the next financial year.
If you are looking to buy this stock, then you may note that the average analyst recommendation by 8 brokerage firm advisors rate Aurinia Pharmaceuticals Inc. (AUPH) as a “Moderate Buy” at a consensus score of 2.10. Specifically, 5 Wall Street analysts polled rate the stock as a buy, while 2 of the 8 advise that investors “hold,” and 0 rated it as a “Sell.”
